This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Japan
Aneropharma Science, Inc. is a privately held drug discovery company, developing a tumor selective therapeutic agent based on its proprietary technology which involves non-pathogenic and anaerobic bacteria. Company?s anti-cancer drug candidate, APS001F is recombinant anaerobic bacteria Bifidobacterium modified to express the cytosine deaminase (CD) gene, which results in overexpression of the CD enzyme.
aRigen Pharmaceuticals, Inc. is a drug discovery and development company with a commitment to discovering breakthrough pharmaceutical seeds in Japan, and developing innovative pharmaceutical products for the entire global population.
Beacle is engaged in research, development, manufacturing and sales of pharmaceutical drugs, healthcare products and laboratory reagents.
BioComo Inc. is a biotech company aiming to bring innovative technology to human health and is dedicated to the research & development of innovative vaccine systems for infectious diseases and malignant tumors based on human parainfluenza type 2 virus vector sysytem.
BioMedCore Inc., a Japanese start-up company with proprietary Liposome Technologies, provides a novel way to continuous mass-production of high-quality GMP glade liposome product with a narrow particle-size distribution, high encapsulation efficiency and sterility.
CanBas Co., Ltd. is a biopharmaceutical company that develops anti-cancer drugs with fewer side effects. The Company's core technologies include drugs that target the G2 checkpoint and a screening system to find selective abrogators of the G2 checkpoint.
Carna Biosciences, Inc. is a preclinical-stage biotechnology company established as a spin off company of Organon (now Merck) leveraging deep understanding of the cell signaling process to develop a robust pipeline of drugs for highly unmet medical needs including cancer, inflammatory diseases and neurological diseases. KC-459 is a potent CDC7/ASK kinase inhibitor with unique mechanistic slow off-rates characteristics, and currently in preclinical development. BTK inhibitor for RA are expected to proceed to the preclinical in 2012 Carna has also discovered a new ?first-in-class? wnt-signal inhibitor for the treatment of cancer and another ?first-in-class? kinase inhibitor for Alzheimer disease that are at late optimization stage. Carna is currently seeking strategic partners and funding for these drug candidates.
Cell-Therapy Technology Institute ("CyTIX") is a biotech company to research, develop and commercialize the Cell Therapy vaccine products for cancer treatment. Phase I/II clinical studies of the lead product "CyTIX-01" (DC+Tumor Fusion Vaccine plus IL-12) for Glioma had DONE with good response.
CellSeed Inc. (parent company of CellSeed Europe Ltd.) is a publicly traded Japanese regenerative medicine company focused on cornea epithelium disorder, myocardial infarction / dilated cardiomyopathy, esophagous cancer and other indications where current treatments fail to meet patient's needs.
D. Western Therapeutics Institute, Inc. (DWTI) is a biotechnology (bio-venture) company that focuses on development of innovative new drugs, especially protein kinase inhibitors. The company discovers and develops several drugs, such as antiglaucoma, antihypertensive, neuroprotective, antithrombogenic, antiatherosclerosis and anticancer.
DNAVEC Corporation is a biotechnology company specializing in vector technologies built upon proprietary cytoplasmic expression system PlasmEx(TM) utilizing RNA virus replicons. They offer gene therapeutic medicines for cardiovascular, respiratory, autoimmune, ophthalmologic, and cancer diseases; gene vaccines for AIDS, tuberculosis, influenza, malaria, tumors, Alzheimer?s, and Parkinson?s diseases; and proteins for medical treatment, research, and in vitro diagnosis.
Evec, Inc. is a bio-venture company having its head office in Sapporo, Japan, established in 2003, spun off from Hokkaido University. Evec is specialized in development of fully human monoclonal antibodies from human peripheral B-lymphocytes by an Epstein-Barr Virus Transformation Method. They are seeking for partners who are interested in our antibodies against Clostridium Difficile, Metapneumovirus, and HMGB1 as well as our antibody technologies.